[HTML][HTML] Artificial intelligence and obesity management: an obesity medicine association (OMA) clinical practice statement (CPS) 2023
HE Bays, A Fitch, S Cuda, S Gonsahn-Bollie, E Rickey… - Obesity Pillars, 2023 - Elsevier
Abstract Background This Obesity Medicine Association (OMA) Clinical Practice Statement
(CPS) provides clinicians an overview of Artificial Intelligence, focused on the management …
(CPS) provides clinicians an overview of Artificial Intelligence, focused on the management …
[HTML][HTML] Obesity, diabetes mellitus, and cardiometabolic risk: an obesity medicine association (OMA) clinical practice statement (CPS) 2023
HE Bays, S Bindlish, TL Clayton - Obesity Pillars, 2023 - Elsevier
Abstract Background This Obesity Medicine Association (OMA) Clinical Practice Statement
(CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), an …
(CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), an …
[HTML][HTML] Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: an Obesity Medical Association (OMA) Clinical …
SE Cuda, R Kharofa, DR Williams, V O'Hara, R Conroy… - Obesity Pillars, 2022 - Elsevier
Abstract Background This Obesity Medicine Association (OMA) Clinical Practice Statement
(CPS) details metabolic, behavioral health, and disordered eating comorbidities associated …
(CPS) details metabolic, behavioral health, and disordered eating comorbidities associated …
Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. Its
incidence is progressively rising and it is possibly becoming a worldwide epidemic. NAFLD …
incidence is progressively rising and it is possibly becoming a worldwide epidemic. NAFLD …
[HTML][HTML] Clinical review: guide to pharmacological management in pediatric obesity medicine
V O'Hara, S Cuda, R Kharofa, M Censani, R Conroy… - Obesity Pillars, 2023 - Elsevier
Introduction Newer pharmacotherapy agents (anti-obesity medication [AOM]) are
revolutionizing the management of children and adolescents with obesity. Previously …
revolutionizing the management of children and adolescents with obesity. Previously …
A Review of the Effects of Fucoxanthin on NAFLD
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease.
Fucoxanthin, a red-orange marine carotenoid, is found in natural marine seaweeds with …
Fucoxanthin, a red-orange marine carotenoid, is found in natural marine seaweeds with …
Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a …
Summary Background The Fibrosis-4 Index (FIB-4) is used as a non-invasive tool for the
presence of advanced liver fibrosis in metabolic dysfunction-associated steatotic liver …
presence of advanced liver fibrosis in metabolic dysfunction-associated steatotic liver …
Malicia honey (Mimosa quadrivalvis L.) produced by the jandaíra bee (Melipona subnitida D.) improves depressive-like behaviour, somatic, biochemical and …
MLR Bezerra, M Gouveia-Nhanca… - Food Research …, 2023 - Elsevier
Malícia honey produced by the jandaíra bee has hypoglycaemic and hypolipidemic effects
and antioxidant activity in vitro and in vivo, which makes it potential adjuvant treatment for …
and antioxidant activity in vitro and in vivo, which makes it potential adjuvant treatment for …
The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan® CAP Values among the Taiwanese Population
MS Lee, EB Felipe-Dimog, JF Yang, YY Chen, KT Wu… - Biomedicines, 2023 - mdpi.com
The controlled attenuation parameter (CAP) measurement obtained from FibroScan® is a
low-risk method of assessing fatty liver. This study investigated the association between the …
low-risk method of assessing fatty liver. This study investigated the association between the …
Rendimiento diagnóstico de ocho marcadores bioquímicos y antropométricos en la enfermedad de hígado graso no alcohólico en pacientes del Centro Materno …
MR Cortés Olano - 2023 - repositorio.urp.edu.pe
Introducción: Hasta el 2019 la EHGNA (enfermedad de hígado graso no alcohólico)
afectaba a más del 30% de la población mundial, hubo un aumento de aproximadamente …
afectaba a más del 30% de la población mundial, hubo un aumento de aproximadamente …